The UT Dallas research focuses on ALS associated with inherited mutations, which account for approximately 5% to 10% of ALS cases. “Our goal is to test in a small animal model the idea of using CRISPR to delete mutations as a one-time treatment for inherited ALS. To address the central problem of delivering AAV-based CRISPR gene therapy across the barriers, the researchers turned to nanotechnology. The UT Dallas team will use a light-sensitive gold nanoparticle for targeting the barriers. Once developed, the technique could be adapted for similar treatments for ALS associated with other inherited genetic mutations.